Liminal BioSciences Inc. (LMNL)

NASDAQ: LMNL · IEX Real-Time Price · USD
0.490
-0.010 (-2.00%)
At close: Aug 10, 2022 3:53 PM
0.471
-0.019 (-3.838%)
After-hours: Aug 10, 2022 7:52 PM EDT

Company Description

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom.

The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases.

It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage.

The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Liminal BioSciences Inc.
Liminal BioSciences Logo
Country Canada
Industry Biotechnology
Sector Health Care
Employees 251
CEO Kenneth Galbraith

Contact Details

Address:
440 Boulevard Armand
Laval, Quebec H7V 4B4
Canada
Phone 450 781 0115
Website liminalbiosciences.com

Stock Details

Ticker Symbol LMNL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency CAD
CIK Code 1351172
CUSIP Number 53272L103
ISIN Number CA53272L1031
SIC Code 2836

Key Executives

Name Position
Bruce Pritchard BA, CA, FIOD Chief Executive Officer
Patrick Sartore President
Marie Iskra Corporate Secretary and General Counsel
N. Nicole Rusaw C.A., CPA Interim Chief Financial Officer
Shrinal Inamdar Manager of Investor Relations and Communications
Dr. Steven J. Burton President of Prometic Bioseparations Ltd
Dr. John Bienenstock CM, FRCP, FRPC, FRSC, M.D.(Hon) Member of Advisory Committee - Therapeutics
Dr. Christopher L. Penney Chief Scientific Officer of Therapeutics - ProMetic BioSciences Inc
Dr. Robert G. Rohwer Member of Scientific Advisory Committee - PRDT
Dr. Volker Helrich Member of Scientific Advisory Committee - Therapeutics

Latest SEC Filings

Date Type Title
Jul 21, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Jun 6, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 24, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 23, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 10, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 9, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 9, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 3, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Apr 1, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Mar 17, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]